Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • Bitcoin CAD

    83,259.62
    -2,699.06 (-3.14%)
     
  • CMC Crypto 200

    1,261.19
    -96.82 (-7.13%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     

Stocks in play: Stantec

Today outlined its three-year strategic plan for the years 2020 to 2022. Stantec also announced several appointments to, and a retirement from, its executive team, as well as its financial guidance for 2020. Stantec’s three-year strategy aims to: Grow earnings per share at a CAGR of greater than 11% by the end of 2022; Deliver a return on invested capital of greater than 10% by the end of 2022. Stantec shares T.STN are trading down $0.32 at $34.90.

Read: Oncolytics Biotech to Highlight Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue at the Fifth Annual Oncolytic Virotherapy Conference